The new approval follows the BiTE's first approval in 2023 for DLBCL.
for the bispecific CD20-directed CD3 T-cell engager. The agent was first approved in 2023 for relapsed or refractory diffuse large
After a two step-up dosing regimen, the overall response rate was 82%, with 60% of patients achieving a complete response. At a median follow-up of 14.8 months, the median duration of response was not reached. The 12-month duration of response was 68.4%.cytokine release syndrome Decreased lymphocyte count, neutrophil count, white blood cell count, and hemoglobin were the most common grade 3/4 laboratory abnormalities.
Non-Hodgkin Lymphoma NHL Follicular Lymphoma Lymphoma Malignant Lymphoma B-Cell Lymphoma Diffuse Large Cell Lymphoma Diffuse Large B-Cell Lymphoma Otolaryngology ENT Specialty Head And Neck Surgery ENT Speciality Toxicology Toxicity Poisoning Toxins Cytokines Refractory Upper Respiratory Infection Upper Respiratory Tract Infection White Blood Cell Count
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US FDA approves Merck's pneumococcal vaccine for adultsUS FDA approves Merck's pneumococcal vaccine for adults
Read more »
FDA approves first menthol e-cigarettes in the USPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
FDA approves first menthol flavored e-cigarettes from Altria's NJOYThe FDA’s authorization comes at a time when the government is reviewing a potential ban on menthol cigarettes.
Read more »
FDA approves first RSV vaccine for at-risk adults in their 50sThe RSV vaccine by GSK was previously approved only for adults 60 and older.
Read more »
FDA approves menthol vapes, drawing criticism from health advocatesThe decision arrives as the FDA is criticized for failing to rein in illegal but widely available flavored vaping products that appeal to young people.
Read more »
FDA Approves Adagrasib for KRAS G12C–Mutated CRCThis marks the first approval for a KRAS inhibitor to treat CRC.
Read more »